Patient, disease, and transplant characteristics after matched-pair analysis
| Characteristic . | PTCY (n = 93) . | ATG (n = 179) . | P . |
|---|---|---|---|
| Age at allo-HSCT, median (range), y | 51 (20-73) | 53 (19-75) | .98 |
| Females/males | 56 (60)/37 (40) | 81 (45)/98 (55) | <.02 |
| Secondary AML | 17 (18) | 36 (20) | .72 |
| Disease status at allo-HSCT | |||
| CR1/CR2/CR3 | 12 (13)/51 (55)/15 (16) | 100 (56)/27 (15)/1 (1) | .76 |
| First relapse/second relapse | 10 (11)/5 (5) | 23 (13)/4 (2) | |
| Primary refractory | 12 (13) | 24 (13) | |
| Karnofsky Performance Status < 90% | 48 (29) | 21 (25) | .48 |
| HLA mismatches | |||
| Class I mismatch | 68 (73) | 134 (75) | |
| A/B/C, n | 31/20/17 | 56/31/47 | |
| Class II mismatch | 25 (27) | 45 (25) | |
| DR/DQ, n | 6/19 | 20/25 | |
| Female donor/male recipient | 10 (11) | 18 (10) | .86 |
| CMV serology | .31 | ||
| D−/R+ | 28 (30) | 68 (38) | |
| D−/R− | 23 (25) | 31 (17) | |
| D+/R− | 3 (3) | 10 (5) | |
| D+/R+ | 39 (42) | 70 (40) | |
| Interval from diagnosis to allo-HSCT (range), mo | 6 (2-47) | 6 (2-63) | .98 |
| Year of allo-HSCT (range) | 2015 (2011-2017) | 2014 (2011-2017) | <.01 |
| Conditioning regimen | |||
| MAC | 47 (50) | 90 (50) | .97 |
| RIC | 46 (50) | 89 (50) | |
| Source of stem cells | |||
| BM | 8 (9) | 15 (8) | .95 |
| PBSCs | 85 (91) | 164(92) | |
| Associated immunosuppressive agents | |||
| Cyclosporine | 13 (14) | 3 (2) | |
| Cyclosporine + mycophenolate mofetil | 39 (42) | 88 (49) | |
| Cyclosporine + methotrexate | 2 (2) | 70 (39) | |
| Tacrolimus + mycophenolate mofetil | 19 (20) | 7 (4) | |
| Other | 20 (22) | 11 (6) | |
| Follow-up, median (range), mo | 14 (2-56) | 27 (2-83) | <.01 |
| Characteristic . | PTCY (n = 93) . | ATG (n = 179) . | P . |
|---|---|---|---|
| Age at allo-HSCT, median (range), y | 51 (20-73) | 53 (19-75) | .98 |
| Females/males | 56 (60)/37 (40) | 81 (45)/98 (55) | <.02 |
| Secondary AML | 17 (18) | 36 (20) | .72 |
| Disease status at allo-HSCT | |||
| CR1/CR2/CR3 | 12 (13)/51 (55)/15 (16) | 100 (56)/27 (15)/1 (1) | .76 |
| First relapse/second relapse | 10 (11)/5 (5) | 23 (13)/4 (2) | |
| Primary refractory | 12 (13) | 24 (13) | |
| Karnofsky Performance Status < 90% | 48 (29) | 21 (25) | .48 |
| HLA mismatches | |||
| Class I mismatch | 68 (73) | 134 (75) | |
| A/B/C, n | 31/20/17 | 56/31/47 | |
| Class II mismatch | 25 (27) | 45 (25) | |
| DR/DQ, n | 6/19 | 20/25 | |
| Female donor/male recipient | 10 (11) | 18 (10) | .86 |
| CMV serology | .31 | ||
| D−/R+ | 28 (30) | 68 (38) | |
| D−/R− | 23 (25) | 31 (17) | |
| D+/R− | 3 (3) | 10 (5) | |
| D+/R+ | 39 (42) | 70 (40) | |
| Interval from diagnosis to allo-HSCT (range), mo | 6 (2-47) | 6 (2-63) | .98 |
| Year of allo-HSCT (range) | 2015 (2011-2017) | 2014 (2011-2017) | <.01 |
| Conditioning regimen | |||
| MAC | 47 (50) | 90 (50) | .97 |
| RIC | 46 (50) | 89 (50) | |
| Source of stem cells | |||
| BM | 8 (9) | 15 (8) | .95 |
| PBSCs | 85 (91) | 164(92) | |
| Associated immunosuppressive agents | |||
| Cyclosporine | 13 (14) | 3 (2) | |
| Cyclosporine + mycophenolate mofetil | 39 (42) | 88 (49) | |
| Cyclosporine + methotrexate | 2 (2) | 70 (39) | |
| Tacrolimus + mycophenolate mofetil | 19 (20) | 7 (4) | |
| Other | 20 (22) | 11 (6) | |
| Follow-up, median (range), mo | 14 (2-56) | 27 (2-83) | <.01 |
Unless otherwise noted, data are n (%).
BM, bone marrow; D, donor; PBSCs, peripheral blood stem cells; R, recipient.